FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
Clinical trials for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA explained in plain language.
Never miss a new study
Get alerted when new FIBRODYSPLASIA OSSIFICANS PROGRESSIVA trials appear
Sign up with your email to follow new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug aims to halt 'Second Skeleton' disease
Disease control OngoingThis Phase 3 trial is testing an experimental drug called garetosmab in adults with fibrodysplasia ossificans progressiva (FOP), a rare disease that causes soft tissues to turn into bone. The main goals are to see if the drug is safe and if it can reduce the number of new abnorma…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New drug trial aims to halt debilitating 'Second Skeleton' disease
Disease control OngoingThis study is testing an experimental drug called andecaliximab for people with fibrodysplasia ossificans progressiva (FOP), a rare and severe condition where muscles and soft tissues turn into bone. The main goal is to see if the drug can safely reduce the formation of new, abno…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
Phase: PHASE2, PHASE3 • Sponsor: Ashibio Inc • Aim: Disease control
Last updated Mar 03, 2026 14:06 UTC
-
New pill tested to halt debilitating 'Second Skeleton' disease
Disease control OngoingThis study is testing whether an oral medication called fidrisertib can slow the formation of new, abnormal bone in people with Fibrodysplasia Ossificans Progressiva (FOP), a rare and severely disabling genetic disease. Researchers will compare two different doses of the drug aga…
Matched conditions: FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
Phase: PHASE2 • Sponsor: Clementia Pharmaceuticals Inc. • Aim: Disease control
Last updated Mar 02, 2026 15:22 UTC